People in the News: Jan 2, 2015

Bernard Tobin 

Myriad Genetics has appointed Bernard Tobin as president of Crescendo Bioscience. Tobin joins Myriad from Amgen, where over the past seven years he has held various leadership roles, including executive director of national accounts, general manager of the Netherlands and Brazil, as well as global head of commercial excellence. Before Amgen, Tobin had worked at Eli Lilly and Co.

Tobin will take over for William Hagstrom and report to Myriad CEO Peter Meldrum. Hagstrom has decided to leave Crescendo to pursue startup and social venture opportunities. He will stay with the company until Jan. 2, 2015, and Tobin's appointment will be effective as of Jan. 5.

David Reiter

Luminex said that Senior VP, General Counsel, and Corporate Secretary David Reiter is resigning from the firm, effective on or around April 1, 2015. The firm said he resigned to pursue other interests and his departure is not the result of any disagreement with the company. Reiter will rejoin his independent legal practice, but he will serve as a consultant to Luminex from the time of his resignation until the end of 2015. 

John Gallagher

Becton Dickinson's board of directors has elected John Gallagher to the new position of vice president, corporate finance. Gallagher will replace Joseph Mercurio as BD's principal accounting officer, while remaining the firm's treasurer. Mercurio is moving to another undisclosed position within BD.

Gallagher was most recently VP of business planning and analysis, and treasurer at BD. Prior to that, he was the company's VP and treasurer from 2012 to 2013. He was VP of financial planning and analysis at NBC Universal before joining BD. 

Jeffrey Boschwitz, Theresa Zhang, Felix Dawson

Personal Genome Diagnostics named Jeffrey Boschwitz its chief operating officer, Theresa Zhang its VP of research services, and Felix Dawson to its board. Boschwitz was formerly executive VP of operations and corporate development at Plus Diagnostics. Prior to that, he was VP of North American sales and marketing at Orchid Cellmark and has held positions at Quest Diagnostics and Booz Allen Hamilton. 

Zhang joins PGDx from Merck Research Laboratories where she held various positions responsible for identification of predictive biomarkers and clinical implementation for oncology compounds. Dawson is a founding member of investment firm Wilkes Lane Capital. He previously was at Constellation Energy, now called Exelon, and at Goldman Sachs.